Data

The Trial Remifentanil DEXmedetomidine (TREX) trial

The University of Melbourne
Access the data

Licence & Rights

Restrictive Licence

Dataset description

This dataset contains individual level perioperative data collected for the short term outcomes analysis of the multicentre TREX phase III randomised controlled trial. Infants less than 2 years of age undergoing general anaesthesia expected to last at least 2 hours were randomised 1:1 to low dose sevoflurane plus dexmedetomidine and remifentanil (LD SEVO) or standard dose sevoflurane (STD SEVO). Data cover intraoperative haemodynamics, anaesthetic events, recovery metrics, pain scores, and morbidity and mortality through postoperative day 5. The dataset enables comparison of the safety and feasibility profiles of LD SEVO vs STD SEVO techniques in early childhood. Prior to releasing any data the following are required: a data access agreement must be signed between relevant parties, the TREX Trial Steering Committee must see and approve the analysis plan describing how the data will be analysed, there must be an agreement around appropriate acknowledgement and any additional costs involved must be covered. Data will only be shared with a recognised research institution which has approved the proposed analysis plan. IPD Sharing Supporting Information Type Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code DOI: 10.1097/ALN.0000000000005232

Date Information

Created from 2026-03-26
Updated from 2026-03-26
Issued from 2026-03-26
Collected from 2017-08-09/2023-04-21
Click to explore relationships graph

Source Study

Purpose:
Not available
Phase:
Not available
Trial acronym

Not available

Trial ID

NCT03089905

Funding

Not available

Scientific enquiries

Brief Summary

There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less .... Read more

Key Inclusion Criteria

Inclusion Criteria: * Younger than 2 years (chronological age) * Scheduled for anaesthesia that is expected to last at least 2 hours (and/or total operating room time is scheduled to be at least 2.5 hours) * Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf. Exclusion Criteria: * Known neurologic, chromosomal or congenital anomaly which is likely to be associated with poor neurobehavioural outcome * Ex .... Read more

Key Exclusion Criteria
Can healthy volunteers participate?

No

Population

Sample Size    Not Available

Min. age    N/A

Max. age    2 Years

Sex    All

Condition category    Not Available

Condition code    Anesthesia , Neurotoxicity , Child Development

Intervention

Intervention code Treatment: Drugs - Sevoflurane , Treatment: Drugs - Remifentanil , Treatment: Drugs - Dexmedetomidine

Sevoflurane/dexmedetomidine/remifentanil Experimental Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr. Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater. Sevoflurane: end tidal concentration of 0.6 -0.8% or less. Sevoflurane Active comparator End tidal concentration of 2.5-3.0% or greater. Treatment: Drugs: Sevoflurane Experimental arm: end tidal concentration of 0.6 -0.8% or less. A ....
Read more

Comparison

Control group Not available

Comparison not available.

Outcomes

Not Available

Will the study consider sharing individual participant data?

Yes

What individual participant data might be shared?

STUDY_PROTOCOL,SAP,ICF,CSR,ANALYTIC_CODE

When can requests for individual participant data be made (start and end dates)?

6 months after publication of primary outcome

Who can request access to individual participant data?

Prior to releasing any data the following are required: a data access agreement must be signed between relevant parties, the TREX Trial Steering Committee must see and approve the analysis plan describing how the data will be analysed, there must be an agreement around appropriate acknowledgement and any additional costs involved must be covered. Data will only be shared with a recognised research institution which has approved the proposed analysis plan.

Source study information is derived from the ClinicalTrials.gov. For more information, please see ClinicalTrials.gov

How is Heath Data Australia supporting health research?

To assist secondary data users in understanding the real-world impact of health and medical research data sharing, the Australian Research Data Commons (ARDC) has created an online guide that outlines a theoretical framework for four key data reuse scenarios. This practical guide was extracted from research papers, and consultation with stakeholders and the research community.

Read the guide

How to access data via Health Data Australia

With Health Data Australia, researchers can explore descriptions of data from our publishing partners, identify relevant datasets, and request access. These requests will then be forwarded to the data owner for review.

To start requesting data, simply login with your AAF account.

Learn more